Key result
Higher baseline plasma ANP levels were associated with an increased risk of developing chronic kidney disease over 7 years, though this association became insignificant after adjusting for age.
Why the study?
Do higher baseline plasma levels of ANP and BNP predict the development of CKD in a general population without prior CKD?
Cohort (n=294)
No
Do higher baseline plasma levels of ANP and BNP predict the development of CKD in a general population without prior CKD?
Answers are grounded in this paper and cite their sources.
Age-related elevation of plasma ANP levels precedes the development of CKD in the general population, suggesting a potential role of this biomarker in identifying early renal impairment risk.
BACKGROUND: Plasma levels of atrial and brain natriuretic peptides (ANP and BNP) are increased in patients with chronic kidney disease (CKD) complicated with deteriorated kidney function, but the relationship between the plasma level of ANP or BNP and the future development of CKD is unclear. METHODS: We measured the plasma ANP and BNP levels of 294 local residents without CKD in a Japanese community (56.5 ± 10.4 years, mean ± S.D.), who were followed up for the development of CKD over the next 7 years. RESULTS: Sixty-three residents developed CKD during the follow-up period, and the baseline level of plasma ANP of these residents was significantly higher than in those without CKD development. Kaplan-Meier analysis showed that the residents with higher ANP than the median value developed CKD more frequently than those with lower ANP. The association between plasma ANP level and CKD development was found to be independent of baseline estimated glomerular filtration rate by a Cox proportional hazards model, while this association became insignificant when adjusted by age; plasma ANP was significantly correlated with age. Compared with ANP, the relationship between plasma BNP and CKD development was unclear in these analyses. CONCLUSIONS: Age-related elevation of plasma ANP levels preceded the development of CKD in the general population of Japan, raising a possibility for ANP being involved in the development of CKD.
No takes yet. Share an insight, caveat, or question.
Ogawa et al. (2015) conducted a cohort in General population without chronic kidney disease (n=294). Elevated plasma ANP level vs. Lower plasma ANP level was evaluated on Development of chronic kidney disease (RR 1.030, 95% CI 1.009-1.052, p=<0.01). Higher baseline plasma ANP levels were associated with an increased risk of developing chronic kidney disease over 7 years, though this association became insignificant after adjusting for age.
Synapse has enriched 10 related papers. Consider them for comparative context: